Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Rocket Pharmaceuticals's RPA-601?
RPA-601 is a gene therapy commercialized by Rocket Pharmaceuticals, with a leading Phase I program in Cardiomyopathy. According to Globaldata,...
Mozafancogene autotemcel by Rocket Pharmaceuticals for Fanconi Anemia: Likelihood of Approval
Mozafancogene autotemcel is under clinical development by Rocket Pharmaceuticals and currently in Phase II for Fanconi Anemia. According to GlobalData,...
RPL-301 by Rocket Pharmaceuticals for Anemia: Likelihood of Approval
RPL-301 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Anemia. According to GlobalData, Phase I...
RPA-601 by Rocket Pharmaceuticals for Cardiomyopathy: Likelihood of Approval
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy. According to GlobalData, Phase I...